India’s pharmaceutical products exports registered over 30% growth during the ten months period from April 2008 to Jan 2009, notwithstanding odds like slowing growth in leading pharma markets worldwide and fluctuating currencies.India’s exports of pharmaceutical products touched Rs.31,607.84 crores during April 08 – January 09, growing at 30.7%, compared to Rs 24,175.9 crores for the same period during previous year, according to Pharmexcil.
Pharmexcil or the Pharmaceuticals Export Promotion Council is the agency set up to oversee exports under the Ministry of Commerce & Industry, Govt. of India.
In terms of US dollars, the figures on exports US$ 6.99 billion compared to US$ 6.08 billion during the same period growing at 16.4%.
In the month of January 2009, exports have grown by 11.5% to Rs 2,916.99 crores compared to Rs 2,616.72 crores in Jan 2008. In US$ terms however, the exports in January 09 declined by 10.1% over January 08.
US remained the largest importer of Indian pharmaceutical products. The exports to United States (US) reached US$ 6.99 billion compared to US$ 6.08 billion during the same period in 2007-08, registering a growth of 16.4 per cent.
Germany was overtaken by Austria for the second position, growing at 1,123.26% reaching US$283.43 from US$23.17. Exports to Germany declined by 12.06%, to China by 20.97%, and Italy by 26.6%
India’s exports to South Africa grew 57.27%. Exports to Belgium (83.2%), Kenya (63.51%), Nigeria (38.79%) and France (33.25%) have also increased significantly during the period under consideration.
The Pharmexcil analysis of top 25 companies, based on the exports data from the Directorate General of Commercial Intelligence & Statistics (DGCI&S) and Centre for Monitoring Indian Economy (CMIE), found that exports to 18 countries recorded a decline during the month of Jan 09 vis-à-vis Jan 08.
The worst fall registered was by Germany, at -34.92%, followed by Spain (-35.21) and Brazil (-30.74%). However, exports to Thailand have gone up during the month by 65.45%.
December 2008 recorded the highest growth in pharmaceutical export during the 10 months period compared to the same period of the previous year.
Exports went up to Rs 4,934.43 crore in December 2008, which is 78.3 per cent higher than the Rs 2,766.78 crore recorded in the same month in 2007.
The increase in exports was also high in November 2008, registering Rs 2,988.72 crore with a 34.1 per cent increase when compared to the exports in November 2007 (Rs 2,228.86 crore), the report said.
The Pharmaceuticals Export Promotion Council (Pharmexcil) was set up on May 12, 2004, as a separate agency to oversee exports in pharmaceutical products.
Pharmexcill is the sole agency to issue Registration-cum-Membership Certificate (RCMCs) to all Pharma exporters.
Pharmexcil’s administration commitee comprises representatives from major pharma companies in India like J B Chemicals & Pharmaceuticals Limited, Suven Life Sciences Limited, Dr. Reddy’s Laboratories, Lupin, Ranbaxy, Novartis, and so on.
It also includes government officials from Central government and the Andhra Pradesh government.
Besides issuing RCMCs, Pharmaxcil organises trade delegations/buyer-seller meetings abroad.
It is involved in organizing reverse buyer-seller meetings in India, assisting members to get their MDA/MAI claims refunded from Govt. of India Issue of Certificate of Origin, and organizing periodical seminars/interactive meetings on exports related issues.
Pharmexcil also makes suggestions to the Government of India on policy issues relating to Pharma exports and makes representations to the government and other agencies in India and abroad to get amicable solutions for the common problems of the industry.
Various pharmaceutical items like Bulk Drugs and its intermediates, formulations, herbal, ayurvedic, unani and homeopathic medicines, biotech and biological products, come under the purview of Pharmexcil.
Pharmexcil also focuses on Diagnostics, surgicals, neutraceuticals, and pharma industry related services, collaborative research, contract manufacturing, clinical trials and consultancy.